RT Journal Article
SR Electronic
T1 Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19006809
DO 10.1101/19006809
A1 Marc A. Egerman
A1 Jenny S. Wong
A1 Tian Runxia
A1 Gohar Mosoyan
A1 Kinsuk Chauhan
A1 Fadi El Salem
A1 Kristin Meliambro
A1 Hong Li
A1 Evren Azeloglu
A1 Steven Coca
A1 Kirk N. Campbell
A1 Leopoldo Raij
YR 2019
UL http://medrxiv.org/content/early/2019/09/16/19006809.abstract
AB Urinary plasminogen/plasmin, or plasmin(ogen)uria, has been demonstrated in proteinuric patients and exposure of cultured podocytes to plasminogen results in injury via oxidative stress pathways. A causative role for plasmin(ogen) as a “second hit” in kidney disease progression has yet to be demonstrated in vivo, and the association between plasmin(ogen)uria and kidney function in glomerular diseases remains unclear. We performed comparative studies in a puromycin aminonucleoside (PAN) nephropathy rat model treated with amiloride, an inhibitor of plasminogen activation, and measured changes in plasmin(ogen)uria and urinary endothelin-1 (ET1). In a glomerular disease biorepository cohort (n=128), we measured time-of-biopsy albuminuria, proteinuria, and plasmin(ogen)uria for correlations with renal outcomes. Increased glomerular plasmin(ogen) was found in PAN rats and FSGS patients. PAN nephropathy was associated with increases in plasmin(ogen)uria, proteinuria, and urinary ET1. Amiloride was protective against PAN-induced glomerular injury, reducing urinary ET1 and oxidative stress. In patients, we found associations between plasmin(ogen)uria and edema status as well as eGFR. Our study demonstrates a role for plasmin(ogen)-induced podocyte injury in the PAN nephropathy model, with amiloride having podocyte-protective properties. In one of largest glomerular disease cohorts to study plasminogen, we validated previous findings while suggesting a potentially novel relationship between plasmin(ogen)uria and eGFR. Together, these findings suggest a role for plasmin(ogen) in mediating glomerular injury and as a viable targetable biomarker for podocyte-sparing treatments.TRANSLATIONAL STATEMENT Proteinuria is associated with CKD progression, and increased cardiovascular morbidity and mortality. The underlying mechanisms of podocyte injury, the hallmark of proteinuric kidney disease, are poorly understood with limited, non-specific therapeutic options. This study adds to the evidence that plasmin(ogen) in the urine of proteinuric patients is associated with podocyte injury, edema, and impaired renal function. Previously published results from us and others, taken together with our current rodent model and human data, suggest that urinary plasmin(ogen) is a potential targetable biomarker. Efforts to decrease plasmin(ogen)-mediated podocyte injury could be part of a novel therapeutic strategy for glomerular disease.Competing Interest StatementSGC reports personal fees and other from RenalytixAI, personal fees from CHF Solutions, personal fees from Quark, personal fees from Takeda, personal fees from Janssen, personal fees and other from pulseData, personal fees from Goldfinch, personal fees from Relypsa, outside the submitted work. KNC has received research funding and consultancy fees from Mallinckrodt Pharmaceuticals and Goldfinch Bio as well as advisory board fees from Retrophin. No conflicts of interest, financial or otherwise, are declared by other author(s).Funding StatementSGC is supported, in part, by the following grants: R01DK115562, U01DK10692, R01HL85757, R01DK112258, and U01OH011326. KNC is supported by NIH/NIDDK R01 grants DK103022 and DK122807. LR is supported by South Florida Veterans Affairs Foundation For Research and Education (SFVAFRE).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesRaw data available upon request